Facebook
X
LinkedIn
Forward
Training clone Course KSP
Pediatric differentiated thyroid cancer (DTC) patients frequently present with lymph node and/or distant (lung) metastases. Such patients warrant an aggressive treatment consisting of surgical removal of all surgically accessible local metastases as well as further treatment with one or more courses of radioiodine therapy (RAI). It is still a subject of debate in literature how much I-131 should be administered to pediatric patients. Patients can either be given a fixed (possibly body weight adjusted) activity or a dosimetry based activity, which is often considerably higher.
Target Audience
Endocrinologists/Pediatric Endocrinologists
Radiologists
Learning Objectives
After participating in this CME activity, participants should be able to:
- Recognize the most recent immune therapy treatments from checkpoint inhibitors to chimeric antigen receptors (CAR) T-cell therapy.
- Compare immune therapy treatment options for kidney cancer patients.
- Manage immune therapy toxicities.
- Illustrate recent advances in radiation and immune therapy treatment.
- Distinguish the appropriate treatment for patients during COVID.
Garrett Auditorium and BEC rooms
Travel
Please call Advantage Travel at 215-555-1212 and ask for the conference travel planner.
Kenneth Burman, M.D., is a Consultant for Medscape and UpToDate; a Reviewer for the Endocrine Fellows Foundation; and has received Institutional Grants for Research from Amgen, Eisei, and Pfizer.
Lynnette Nieman, M.D., is an Author/Editor for UpToDate, and receives Research Support from HRA-Pharmaceutical.
Accreditation & Credit Statements
Baptist Memorial Health Care Corporation (BMHCC) is accredited by the Southern States CME Collaborative to provide continuing medical education for physicians.
BMHCC designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statements
It is the policy of Baptist Memorial Health Care Corporation (BMHCC) to promote balance, independence, objectivity, and scientific rigor in all educational activities; to require disclosure of all financial relationships with ineligible companies from individuals in control of educational content; to identify and mitigate relevant financial relationships; and to disclose relevant relationships, or lack thereof, to the audience prior to the CE activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.
Available Credit
- 4.00 EthosCE University